1
|
Zhang X, Wang D, Chang M, Wang W, Shen Z, Xu X. CuBr-mediated synthesis of 1,4-naphthoquinones via ring expansion of 2-aryl-1,3-indandiones. Chem Commun (Camb) 2023; 59:12326-12329. [PMID: 37753616 DOI: 10.1039/d3cc03753c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/28/2023]
Abstract
A CuBr-mediated direct insertion of alkenes into unstrained ring 2-aryl-1,3-indandiones is reported, which provides a one-carbon ring expansion strategy for the synthesis of 1,4-naphthoquinones. Entirely differing from the existing reports, the alkenes herein behave as C1 units to participate in annulation reactions. This transformation provides a facile route to access a class of highly functionalized 1,4-naphthoquinones with good yields, good functional-group tolerance and high atom-economy. Further research on the application of this reaction is currently underway in our laboratory.
Collapse
Affiliation(s)
- Xu Zhang
- College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China.
| | - Di Wang
- College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China.
| | - Mengfan Chang
- College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China.
| | - Wanya Wang
- College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China.
| | - Zhi Shen
- College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China.
| | - Xuefeng Xu
- College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China.
| |
Collapse
|
2
|
Aminoquinolones and Their Benzoquinone Dimer Hybrids as Modulators of Prion Protein Conversion. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27227935. [PMID: 36432036 PMCID: PMC9693643 DOI: 10.3390/molecules27227935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 10/21/2022] [Accepted: 11/10/2022] [Indexed: 11/18/2022]
Abstract
Prion Diseases or Transmissible Spongiform Encephalopathies are neurodegenerative conditions associated with a long incubation period and progressive clinical evolution, leading to death. Their pathogenesis is characterized by conformational changes of the cellular prion protein-PrPC-in its infectious isoform-PrPSc-which can form polymeric aggregates that precipitate in brain tissues. Currently, there are no effective treatments for these diseases. The 2,5-diamino-1,4-benzoquinone structure is associated with an anti-prion profile and, considering the biodynamic properties associated with 4-quinolones, in this work, 6-amino-4-quinolones derivatives and their respective benzoquinone dimeric hybrids were synthesized and had their bioactive profile evaluated through their ability to prevent prion conversion. Two hybrids, namely, 2,5-dichloro-3,6-bis((3-carboxy-1-pentyl-4-quinolone-6-yl)amino)-1,4-benzoquinone (8e) and 2,5-dichloro-3,6-bis((1-benzyl-3-carboxy-4-quinolone-6-yl)amino)-1,4-benzoquinone (8f), stood out for their prion conversion inhibition ability, affecting the fibrillation process in both the kinetics-with a shortening of the lag phase-and thermodynamics and their ability to inhibit the formation of protein aggregates without significant cytotoxicity at ten micromolar.
Collapse
|
3
|
Zhou B, Liu Q, Wang H, Jin H, Liu Y. CuI/Cu(OTf)2/DMSO system-catalyzed intramolecular oxidative cyclization of (o-alkynyl)arylketones: Efficient synthesis of 1,4-naphthoquinones. Tetrahedron 2019. [DOI: 10.1016/j.tet.2019.05.066] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
4
|
Rational approach to an antiprion compound with a multiple mechanism of action. Future Med Chem 2015; 7:2113-20. [DOI: 10.4155/fmc.15.79] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: The main pathogenic event of prion disorders has been identified in the deposition of the disease-associated prion protein (PrPSc), which is accompanied by metal dyshomeostasis. Results: The multitarget-directed ligand 1, designed by combining a heteroaromatic prion recognition motif to an 8-hydroxyquinoline metal chelator, has been developed as a potential antiprion disease-modifying agent. Importantly, 1 was found to effectively clear PrPSc from scrapie-infected cells, and, at the same time, inhibit metal-induced prion aggregation and reactive oxygen species generation. 1 was also characterized in terms of pharmacokinetic properties in a preliminary in vitro investigation. Conclusion: Compound 1 has emerged as a suitable lead candidate against prion diseases and as a good starting point for a further optimization process.
Collapse
|
5
|
Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. Future Med Chem 2014; 6:1017-29. [DOI: 10.4155/fmc.14.56] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Prion diseases (PrDs) are fatal neurodegenerative disorders, for which no effective therapeutic and diagnostic tools exist. The main pathogenic event has been identified as the misfolding of a disease-associated prion protein. Nevertheless, pathogenesis seems to involve an intricate array of concomitant processes. Thus, it may be unlikely that drugs acting on single targets can effectively control PrDs. In addition, diagnosis occurs late in the disease process, by which point it is difficult to determine a successful therapeutic intervention. In this context, multitarget ligands (MTLs) and theranostic ligands (TLs) emerge for their potential to effectively cure and diagnose PrDs. In this review, we discuss the medicinal chemistry challenges of identifying novel MTLs and TLs against PrDs, and envision their impact on prion drug discovery.
Collapse
|
6
|
Quinacrine promotes replication and conformational mutation of chronic wasting disease prions. Proc Natl Acad Sci U S A 2014; 111:6028-33. [PMID: 24711410 DOI: 10.1073/pnas.1322377111] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Quinacrine's ability to reduce levels of pathogenic prion protein (PrP(Sc)) in mouse cells infected with experimentally adapted prions led to several unsuccessful clinical studies in patients with prion diseases, a 10-y investment to understand its mechanism of action, and the production of related compounds with expectations of greater efficacy. We show here, in stark contrast to this reported inhibitory effect, that quinacrine enhances deer and elk PrP(Sc) accumulation and promotes propagation of prions causing chronic wasting disease (CWD), a fatal, transmissible, neurodegenerative disorder of cervids of uncertain zoonotic potential. Surprisingly, despite increased prion titers in quinacrine-treated cells, transmission of the resulting prions produced prolonged incubation times and altered PrP(Sc) deposition patterns in the brains of diseased transgenic mice. This unexpected outcome is consistent with quinacrine affecting the intrinsic properties of the CWD prion. Accordingly, quinacrine-treated CWD prions were comprised of an altered PrP(Sc) conformation. Our findings provide convincing evidence for drug-induced conformational mutation of prions without the prerequisite of generating drug-resistant variants of the original strain. More specifically, they show that a drug capable of restraining prions in one species/strain setting, and consequently used to treat human prion diseases, improves replicative ability in another and therefore force reconsideration of current strategies to screen antiprion compounds.
Collapse
|
7
|
Prati F, Uliassi E, Bolognesi ML. Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases. MEDCHEMCOMM 2014. [DOI: 10.1039/c4md00069b] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Multitarget drug discovery may represent a promising therapeutic approach to treat Alzheimer's and neglected tropical diseases.
Collapse
Affiliation(s)
- F. Prati
- Department of Drug Discovery & Development
- Istituto Italiano di Tecnologia
- Genova
- Italy
- Department of Pharmacy & Biotechnology
| | - E. Uliassi
- Department of Pharmacy & Biotechnology
- University of Bologna
- Bologna
- Italy
| | - M. L. Bolognesi
- Department of Pharmacy & Biotechnology
- University of Bologna
- Bologna
- Italy
| |
Collapse
|
8
|
Prati F, Bartolini M, Simoni E, De Simone A, Pinto A, Andrisano V, Bolognesi ML. Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer’s disease. Bioorg Med Chem Lett 2013; 23:6254-8. [DOI: 10.1016/j.bmcl.2013.09.091] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Revised: 09/24/2013] [Accepted: 09/27/2013] [Indexed: 02/01/2023]
|
9
|
Venko K, Župerl Š, Novič M. Prediction of antiprion activity of therapeutic agents with structure–activity models. Mol Divers 2013; 18:133-48. [DOI: 10.1007/s11030-013-9477-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 08/31/2013] [Indexed: 10/26/2022]
|
10
|
Wrench AP, Gardner CL, Gonzalez CF, Lorca GL. Identification of a small molecule that modifies MglA/SspA interaction and impairs intramacrophage survival of Francisella tularensis. PLoS One 2013; 8:e54498. [PMID: 23372736 PMCID: PMC3553074 DOI: 10.1371/journal.pone.0054498] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Accepted: 12/13/2012] [Indexed: 12/26/2022] Open
Abstract
The transcription factors MglA and SspA of Francisella tularensis form a heterodimer complex and interact with the RNA polymerase to regulate the expression of the Francisella pathogenicity island (FPI) genes. These genes are essential for this pathogen’s virulence and survival within host cells. In this study, we used a small molecule screening to identify quinacrine as a thermal stabilizing compound for F. tularensis SCHU S4 MglA and SspA. A bacterial two-hybrid system was used to analyze the in vivo effect of quinacrine on the heterodimer complex. The results show that quinacrine affects the interaction between MglA and SspA, indicated by decreased β-galactosidase activity. Further in vitro analyses, using size exclusion chromatography, indicated that quinacrine does not disrupt the heterodimer formation, however, changes in the alpha helix content were confirmed by circular dichroism. Structure-guided site-directed mutagenesis experiments indicated that quinacrine makes contact with amino acid residues Y63 in MglA, and K97 in SspA, both located in the “cleft” of the interacting surfaces. In F. tularensis subsp. novicida, quinacrine decreased the transcription of the FPI genes, iglA, iglD, pdpD and pdpA. As a consequence, the intramacrophage survival capabilities of the bacteria were affected. These results support use of the MglA/SspA interacting surface, and quinacrine’s chemical scaffold, for the design of high affinity molecules that will function as therapeutics for the treatment of Tularemia.
Collapse
Affiliation(s)
- Algevis P Wrench
- Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, Florida, United States of America
| | | | | | | |
Collapse
|
11
|
Galdeano C, Viayna E, Sola I, Formosa X, Camps P, Badia A, Clos MV, Relat J, Ratia M, Bartolini M, Mancini F, Andrisano V, Salmona M, Minguillón C, González-Muñoz GC, Rodríguez-Franco MI, Bidon-Chanal A, Luque FJ, Muñoz-Torrero D. Huprine–Tacrine Heterodimers as Anti-Amyloidogenic Compounds of Potential Interest against Alzheimer’s and Prion Diseases. J Med Chem 2012; 55:661-9. [DOI: 10.1021/jm200840c] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Carles Galdeano
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Elisabet Viayna
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Irene Sola
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Xavier Formosa
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
| | - Pelayo Camps
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Albert Badia
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - M. Victòria Clos
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - Júlia Relat
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - Míriam Ratia
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - Manuela Bartolini
- Department
of Pharmaceutical
Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126 Bologna, Italy
| | - Francesca Mancini
- Department
of Pharmaceutical
Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126 Bologna, Italy
| | - Vincenza Andrisano
- Department
of Pharmaceutical
Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126 Bologna, Italy
| | - Mario Salmona
- Department of Molecular Biochemistry
and Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
| | - Cristina Minguillón
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
| | | | | | - Axel Bidon-Chanal
- Departament de Fisicoquímica,
Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028 Barcelona, Spain
| | - F. Javier Luque
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
- Departament de Fisicoquímica,
Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028 Barcelona, Spain
| | - Diego Muñoz-Torrero
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| |
Collapse
|
12
|
Rao MLN, Giri S. Pd-catalyzed threefold arylations of mono, di and tetra-bromoquinones using triarylbismuth reagents. RSC Adv 2012. [DOI: 10.1039/c2ra22058j] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
|
13
|
Multitargeted drugs discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg Med Chem Lett 2011; 21:2655-8. [DOI: 10.1016/j.bmcl.2010.12.093] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2010] [Revised: 12/17/2010] [Accepted: 12/20/2010] [Indexed: 01/06/2023]
|
14
|
Bongarzone S, Tran HNA, Cavalli A, Roberti M, Rosini M, Carloni P, Legname G, Bolognesi ML. Hybrid Lipoic Acid Derivatives to Attack Prion Disease on Multiple Fronts. ChemMedChem 2011; 6:601-5. [DOI: 10.1002/cmdc.201100072] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2011] [Indexed: 11/12/2022]
|
15
|
Ai Tran HN, Sousa F, Moda F, Mandal S, Chanana M, Vimercati C, Morbin M, Krol S, Tagliavini F, Legname G. A novel class of potential prion drugs: preliminary in vitro and in vivo data for multilayer coated gold nanoparticles. NANOSCALE 2010; 2:2724-2732. [PMID: 20944860 DOI: 10.1039/c0nr00551g] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Gold nanoparticles coated with oppositely charged polyelectrolytes, such as polyallylamine hydrochloride and polystyrenesulfonate, were examined for potential inhibition of prion protein aggregation and prion (PrPSc) conversion and replication. Different coatings, finishing with a positive or negative layer, were tested, and different numbers of layers were investigated for their ability to interact and reduce the accumulation of PrPSc in scrapie prion infected ScGT1 and ScN2a cells. The particles efficiently hampered the accumulation of PrPSc in ScN2a cells and showed curing effects on ScGT1 cells with a nanoparticle concentration in the picomolar range. Finally, incubation periods of prion-infected mice treated with nanomolar concentrations of gold nanoparticles were significantly longer compared to untreated controls.
Collapse
Affiliation(s)
- Hoang Ngoc Ai Tran
- Laboratory of Prion Biology, Neurobiology Sector, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Ed. Q1, Basovizza Campus, S.S.14 Km. 163,5, 34149, Trieste, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bongarzone S, Tran HNA, Cavalli A, Roberti M, Carloni P, Legname G, Bolognesi ML. Parallel Synthesis, Evaluation, and Preliminary Structure−Activity Relationship of 2,5-Diamino-1,4-benzoquinones as a Novel Class of Bivalent Anti-Prion Compound. J Med Chem 2010; 53:8197-201. [DOI: 10.1021/jm100882t] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Salvatore Bongarzone
- Statistical and Biological Physics Sector, Neurobiology Sector, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Via Bonomea 265, 34136 Trieste, Italy
- Italian Institute of Technology, SISSA-ISAS Unit, 34151 Trieste, Italy
| | | | - Andrea Cavalli
- Department of Pharmaceutical Sciences, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
- Department of Drug Discovery and Development, Italian Institute of Technology, 16163 Genova, Italy
| | - Marinella Roberti
- Department of Pharmaceutical Sciences, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Paolo Carloni
- Statistical and Biological Physics Sector, Neurobiology Sector, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Via Bonomea 265, 34136 Trieste, Italy
- Italian Institute of Technology, SISSA-ISAS Unit, 34151 Trieste, Italy
- CNR-INFM-DEMOCRITOS Modeling Center for Research in Atomistic Simulation, 34151 Trieste, Italy
| | - Giuseppe Legname
- Department of Pharmaceutical Sciences, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Maria Laura Bolognesi
- Department of Pharmaceutical Sciences, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| |
Collapse
|